A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase II Study to Assess the Efficacy of 28 Day Oral Administration of AZD1236 in Adult Patients With Cystic Fibrosis.

Trial Profile

A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase II Study to Assess the Efficacy of 28 Day Oral Administration of AZD1236 in Adult Patients With Cystic Fibrosis.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2009

At a glance

  • Drugs AZD 1236 (Primary)
  • Indications Cystic fibrosis
  • Focus Therapeutic Use
  • Acronyms CYBER
  • Most Recent Events

    • 07 May 2009 Actual initiation date changed from 1 Jan 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.
    • 07 May 2009 Planned end date changed from 1 Nov 2009 to 1 Aug 2010 as reported by ClinicalTrials.gov.
    • 02 May 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top